Skip to main content
Fig. 1 | Trials

Fig. 1

From: Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Fig. 1

Participant timeline. Patients (n = 244) using secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, or tildrakizumab will be randomized to dose reduction or usual care. Control visits will be scheduled every 3 months for assessment of PASI, DLQI, cost-effectiveness questionnaires (EQ-5D-5L, SF-36, iMTA MCQ, and PCQ), drug levels, and anti-drug antibodies. CEQ, Cost-Effectiveness Questionnaires; PASI, Psoriasis Area and Severity Index; DLQI, Dermatology Life Quality Index

Back to article page

Trials

ISSN: 1745-6215